

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

PROPOSED STEP-DOWN AND RETIREMENT OF DIRECTORS

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Tian Zhoushan (“**Mr. Tian**”) and Mr. Li Dakui (“**Mr. Li**”) are subject to retirement by rotation at the forthcoming annual general meeting of the Company to be held on 17 June 2026 (the “**2026 AGM**”). The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that Mr. Tian and Mr. Li have notified the Company that each of them will retire from office as an executive Director and as an independent non-executive Director, respectively, with effect from the conclusion of the 2026 AGM and will not offer himself for re-election. Mr. Tian’s step-down is due to the reallocation of responsibilities within the Group, and he will remain and continue with his management functions in the Group. Mr. Li’s retirement is due to his reaching retirement age. Upon conclusion of the 2026 AGM, Mr. Li will also cease to be a member of the audit committee of the Company.

Mr. Tian and Mr. Li have confirmed that they have no disagreement with the Board and that there is no matter relating to their step-down/retirement which needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to express its sincere gratitude to Mr. Tian and Mr. Li for their valuable contributions to the Company during their tenures of office.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 29 April 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.